These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 11550394)

  • 1. Rest easy, statin users. Benefits dwarf risks for these cholesterol drugs.
    Comarow A
    US News World Rep; 2001 Sep; 131(8):45. PubMed ID: 11550394
    [No Abstract]   [Full Text] [Related]  

  • 2. Baycol withdrawn from market.
    SoRelle R
    Circulation; 2001 Aug; 104(8):E9015-6. PubMed ID: 11521677
    [No Abstract]   [Full Text] [Related]  

  • 3. Bayer decides to withdraw cholesterol lowering drug.
    Charatan F
    BMJ; 2001 Aug; 323(7309):359. PubMed ID: 11509419
    [No Abstract]   [Full Text] [Related]  

  • 4. [Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States].
    Saito M; Hirata-Koizumi M; Miyake S; Hasegawa R
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2005; (123):41-5. PubMed ID: 16541751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.
    Chang JT; Staffa JA; Parks M; Green L
    Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):417-26. PubMed ID: 15269925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two new drugs for homozygous familial hypercholesterolemia: managing benefits and risks in a rare disorder.
    Smith RJ; Hiatt WR
    JAMA Intern Med; 2013 Sep; 173(16):1491-2. PubMed ID: 23649296
    [No Abstract]   [Full Text] [Related]  

  • 7. Bayer pulls cerivastatin (Baycol) from market.
    Wooltorton E
    CMAJ; 2001 Sep; 165(5):632. PubMed ID: 11563216
    [No Abstract]   [Full Text] [Related]  

  • 8. Substituting for cerivastatin (Baycol).
    Med Lett Drugs Ther; 2001 Sep; 43(1113):79-80. PubMed ID: 11581579
    [No Abstract]   [Full Text] [Related]  

  • 9. Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis.
    McAdams M; Staffa J; Dal Pan G
    Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):229-39. PubMed ID: 18175291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bayer lapse exposes pharma's vulnerability.
    Hodgson J
    Nat Biotechnol; 2001 Oct; 19(10):897-8. PubMed ID: 11581642
    [No Abstract]   [Full Text] [Related]  

  • 11. Weighing the benefits of high-dose simvastatin against the risk of myopathy.
    Egan A; Colman E
    N Engl J Med; 2011 Jul; 365(4):285-7. PubMed ID: 21675881
    [No Abstract]   [Full Text] [Related]  

  • 12. [Massive rhabdomyolysis associated with the use of cerivastatin monotherapy].
    Vera M; Pou M; Botey A; Cases A
    Nefrologia; 2001; 21(6):613-4. PubMed ID: 11881437
    [No Abstract]   [Full Text] [Related]  

  • 13. Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.
    Schmidt GA; Hoehns JD; Purcell JL; Friedman RL; Elhawi Y
    J Am Board Fam Med; 2007; 20(4):411-6. PubMed ID: 17615423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Muscular adverse effects of statins.
    Prescrire Int; 2003 Feb; 12(63):21. PubMed ID: 12602397
    [No Abstract]   [Full Text] [Related]  

  • 15. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis.
    Harper CR; Jacobson TA
    Curr Opin Lipidol; 2007 Aug; 18(4):401-8. PubMed ID: 17620856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Rhabdomyolysis following cerivastatin monotherapy--implications for therapy with HMG-CoA reductase inhibitors].
    Sparing R; Sellhaus B; Noth J; Block F
    Nervenarzt; 2003 Feb; 74(2):167-71. PubMed ID: 12596018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Information regarding adverse drug effects and treatment indications ("package inserts") exemplified by cervistatin (Lipobay)].
    Braun RN; Halhuber MJ; Hitzenberger G
    Wien Med Wochenschr; 2003; 153(3-4):80-2. PubMed ID: 12658968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. These drugs don't mix.
    Nursing; 2008 Oct; 38(10):12. PubMed ID: 18812982
    [No Abstract]   [Full Text] [Related]  

  • 19. Risk for fatal statin-induced rhabdomyolysis as a consequence of misinterpretation of 'evidence-based medicine'.
    Eriksson M; Angelin B; Sjöberg S
    J Intern Med; 2005 Mar; 257(3):313-4. PubMed ID: 15715689
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA panel vetoes OTC version of cholesterol drug.
    Walczak IM
    Diabetes Technol Ther; 2000; 2(3):484. PubMed ID: 11467353
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.